These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 15261566)
1. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. Gonsette RE; Dubois B J Neurol Sci; 2004 Aug; 223(1):81-6. PubMed ID: 15261566 [TBL] [Abstract][Full Text] [Related]
2. New immunosuppressants with potential implication in multiple sclerosis. Gonsette RE J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567 [TBL] [Abstract][Full Text] [Related]
3. Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. Cavaletti G; Cavalletti E; Crippa L; Di Luccio E; Oggioni N; Mazzanti B; Biagioli T; Sala F; Sala V; Frigo M; Rota S; Tagliabue E; Stanzani L; Galbiati S; Rigolio R; Zoia C; Tredici G; Perseghin P; Dassi M; Riccio P; Lolli F J Neuroimmunol; 2004 Jun; 151(1-2):55-65. PubMed ID: 15145604 [TBL] [Abstract][Full Text] [Related]
4. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
5. Rationale for the use of mitoxantrone in multiple sclerosis. Edan G; Morrissey S; Le Page E J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558 [TBL] [Abstract][Full Text] [Related]
6. [Mitoxantrone for the treatment of patients with multiple sclerosis]. Komori M; Kondo T; Tanaka M Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of mitoxantrone in multiple sclerosis--what is known? Neuhaus O; Kieseier BC; Hartung HP J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556 [TBL] [Abstract][Full Text] [Related]
9. Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. Fassas A; Kimiskidis VK J Neurol Sci; 2004 Aug; 223(1):53-8. PubMed ID: 15261561 [TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study. Putzki N; Kumar M; Kreuzfelder E; Grosse-Wilde H; Diener HC; Limmroth V Eur Neurol; 2009; 61(1):27-32. PubMed ID: 18948697 [TBL] [Abstract][Full Text] [Related]
11. Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. Mazzanti B; Biagioli T; Aldinucci A; Cavaletti G; Cavalletti E; Oggioni N; Frigo M; Rota S; Tagliabue E; Ballerini C; Massacesi L; Riccio P; Lolli F J Neuroimmunol; 2005 Nov; 168(1-2):111-7. PubMed ID: 16120465 [TBL] [Abstract][Full Text] [Related]
12. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. Jeffery DR J Neurol Sci; 2004 Aug; 223(1):41-6. PubMed ID: 15261559 [TBL] [Abstract][Full Text] [Related]
13. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities. Stuart WH Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719 [TBL] [Abstract][Full Text] [Related]
15. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. Gonsette RE Expert Opin Pharmacother; 2004 Apr; 5(4):747-65. PubMed ID: 15102561 [TBL] [Abstract][Full Text] [Related]
17. Something Old, New, Borrowed, Blue: Anthracenedione Agents for Treatment of Multiple Sclerosis. Koffman BM; Hacker M; Gunning WT; Quinn A Clin Neuropharmacol; 2016; 39(2):102-11. PubMed ID: 26966886 [TBL] [Abstract][Full Text] [Related]
18. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]